<br />
DERMATOLOGY<br />
EMJ Dermatol. 2019 Suppl 6 • europeanmedical-journal.com<br />
INSIDE<br />
Spotlight on Acne<br />
Spotlight on Acne<br />
This symposium took place on 13th June 2019, as part of the World<br />
Congress of Dermatology (WCD) symposium in Milan, Italy<br />
Chairpeople: Jerry Tan1<br />
Speakers: Gabriella Fabbrocini,2 Linda Stein Gold,3 Jerry Tan1<br />
1. University of Western Ontario and Windsor Clinical Research Inc., Windsor,<br />
Ontario, Canada<br />
2. University of Naples Federico II, Naples, Italy<br />
3. Henry Ford Health System, Detroit, Michigan, USA<br />
Disclosure: Prof Tan is an advisor, consultant, investigator, and/or speaker for: Almirall, Bausch<br />
Health, Boots Walgreens, Botanix, Galderma, Novan, Novartis, and Sun. Prof<br />
Fabbrocini reports financial support from Abbvie SR<a title="EMJ Dermatol. 2019 Suppl 6 page 1" href="http://viewer.zmags.com/publication/9dc7b0bd?page=1"> DERMATOLOGY EMJ Dermatol. 2019 Suppl 6 • european</a>
<a title="EMJ Dermatol. 2019 Suppl 6 page 2" href="http://viewer.zmags.com/publication/9dc7b0bd?page=2"> Spotlight on Acne This symposium took place on 1</a>
<a title="EMJ Dermatol. 2019 Suppl 6 page 3" href="http://viewer.zmags.com/publication/9dc7b0bd?page=3"> the impact of the inflammatory process on the risk</a>
<a title="EMJ Dermatol. 2019 Suppl 6 page 4" href="http://viewer.zmags.com/publication/9dc7b0bd?page=4"> temporary benefit in patients with sever</a>
<a title="EMJ Dermatol. 2019 Suppl 6 page 5" href="http://viewer.zmags.com/publication/9dc7b0bd?page=5"> Products with robust clinical efficacy and safety</a>
<a title="EMJ Dermatol. 2019 Suppl 6 page 6" href="http://viewer.zmags.com/publication/9dc7b0bd?page=6"> Acne Scarring Acne and acne scarring can hav</a>
<a title="EMJ Dermatol. 2019 Suppl 6 page 7" href="http://viewer.zmags.com/publication/9dc7b0bd?page=7"> Current and Emerging Treatments for Unmet</a>
<a title="EMJ Dermatol. 2019 Suppl 6 page 8" href="http://viewer.zmags.com/publication/9dc7b0bd?page=8"> side (from 11.1 to 11.6) (p=0.036).51 At baseline</a>
<a title="EMJ Dermatol. 2019 Suppl 6 page 9" href="http://viewer.zmags.com/publication/9dc7b0bd?page=9"> PErFEcT1 IGA success rate IGA success (%) 50 45</a>
<a title="EMJ Dermatol. 2019 Suppl 6 page 10" href="http://viewer.zmags.com/publication/9dc7b0bd?page=10"> 4. Thiboutot D et al. New insights into </a>
<a title="EMJ Dermatol. 2019 Suppl 6 page 11" href="http://viewer.zmags.com/publication/9dc7b0bd?page=11"> Eur J Dermatol. 2017;27(4):393-8. 49. Layton AM </a>